$DVLT

Vivasor, Inc. sold $1.3M of DVLT

Vivasor, Inc. sold 2,267,338 shares of Datavault AI Inc. (DVLT) at $0.55 ($1.25M total) on 2026-05-06.

Original reporting
SEC EDGAR · Vivasor, Inc.
Published Jun 3, 2026, 12:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DVLT
Bearish
medium confidence
Mentioned
$DVLT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DVLTBearishLow
01

Why it matters

The disclosure updates the insider ownership picture and may influence short-term sentiment, but it does not introduce new company fundamentals in the article.

02

Market read

Traders may reassess near-term sentiment toward DVLT due to a disclosed insider sale, but without additional catalysts the impact is likely limited.

03

What to watch

No 10b5-1 plan is stated, but the filing alone doesn’t reveal motive, tax needs, or whether other insiders/funds acted similarly.

Relevance 6/10Novelty 7/10Timing: Filed June 2; sale dated May 6 (use for positioning around recent trading window).

Background

This is an SEC Form 4 insider transaction disclosure for Datavault AI Inc. (DVLT).

Company-level read

Ticker impact

$DVLTBearishMedium confidence
Context

SEC Form 4 shows 10% owner Vivasor, Inc. sold 2,267,338 DVLT shares in an open-market transaction for ~$1.25M.

Expected impact

Likely limited/short-lived negative drift unless follow-on selling or other news emerges.

Evidence & confidence

The filing is a disclosed sale (not a purchase) and lacks a 10b5-1 plan, but the article provides no new operating/financial development.

Market effects

Minimal—single-company insider sale with no sector-wide signal provided.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity/portfolio management rather than a bearish signal, especially given the large remaining holdings.

Key entities

  • Datavault AI Inc.

    Subject of the Form 4 insider transaction; 10% owner sold DVLT shares.

  • Vivasor, Inc.

    Reporter of the open-market sale of DVLT shares.

Related articles

$DVLTMed

Datavault AI Hit With Securities Lawsuit

Datavault AI Inc. (NASDAQ: DVLT) faces a new securities class action, according to DJS Law Group, alleging the company misled investors about operations, partnerships, and growth prospects. The proposed class period is Sept. 4, 2024 to Oct. 30, 2025. The claims stem largely from a Wolfpack Research report that preceded a ~19% one-day share drop. Lead plaintiff deadline is Oct. 5, 2026.

$DVLTMed

Pomerantz Law Firm Announces the Filing of a Class Action Against Datavault AI Inc. and Certain Officers - DVLT

Pomerantz LLP said it filed a securities class action against Datavault AI Inc. (NASDAQ: DVLT) and certain officers in the Eastern District of Pennsylvania, covering purchases from Sept. 4, 2024 to Oct. 30, 2025. The suit alleges misleading statements about partnerships, trading activity, and compliance. After a Wolfpack Research report on Oct. 31, 2025, DVLT shares fell 19.44% to $2.03.

$DVLTMed

Datavault AI Expands Data Driven Outcome Healthcare

Datavault AI (NASDAQ:DVLT) said it amended its definitive agreement with DataMeds AI (NASDAQ:MEDS) to expand a PharmacyChain blockchain technology licensing relationship into unencumbered commercial healthcare, healthspan and wellness uses. Datavault AI will receive common shares worth about 19.9% of DataMeds’ stock at closing, replacing preferred shares for tax optimization.

$MEDSMed

DataMEDS AI, Inc.: DataMeds AI Expands License with DataVault AI for Data Driven Outcome Healthcare-focused Blockchain and Data Monetization License

DataMeds AI (NASDAQ:MEDS) said it amended its licensing agreement with Datavault AI (NASDAQ:DVLT) to expand PharmacyChain blockchain-related licensing from pharmaceutical distribution to all unencumbered commercial healthcare, healthspan and wellness uses. The deal is tied to a pending multi-party combination and includes DVLT receiving common shares worth about 19.9% of MEDS at closing.